All Oncology News

Maurie Markman, MD, discusses the need to reevaluate how adverse effects are measured and reported with antineoplastic therapies in oncology.

Upcoming oncology meetings in the second half of 2025 will present new data across tumor types and offering updates that may influence standards of care.

Thomas Powles, MD, MBBS, MRCP, discusses challenges in identifying a predictive biomarker of response for sasanlimab in high-risk, BCG-naive NMIBC.

The FDA issued a complete response letter for subcutaneous daratumumab plus VRd in transplant-ineligible, newly diagnosed myeloma.

Ribociclib plus trastuzumab and an AI produced a median PFS of 30.4 months in patients with hormone receptor–positive, HER2-positive breast cancer.

Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts.

The NCCN guidelines for NSCLC were updated to include zongertinib as a preferred subsequent therapy option for advanced or metastatic HER2-mutant NSCLC.

Magrolimab plus nivolumab and FOLFOX with bevacizumab or cetuximab yielded responses in advanced/recurrent colorectal cancer.

The NMPA has granted breakthrough therapy designation to ATG-022 for previously treated gastric and gastroesophageal junction adenocarcinoma.

Jill Gilbert, MD discusses how being coachable and using feedback effectively can drive personal growth, team success, and continuous professional improvement.

Anlotinib plus epirubicin conferred a significant PFS benefit vs epirubicin monotherapy in advanced soft tissue sarcoma.

JAVELIN Bladder Medley data show PFS improvement with avelumab plus sacituzumab govitecan as first-line maintenance vs avelumab alone in urothelial cancer.

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, details the rationale for evaluating the trispecific antibody JNJ-5322 in relapsed/refractory multiple myeloma.

Research shows that blocking CXCR2 receptor reduced tumor growth and improved survival; clinical trial underway.

The FDA has granted breakthrough therapy designation to ifinatamab deruxtecan for the treatment of patients with extensive-stage small cell lung cancer.

Izalontamab brengitecan earned FDA breakthrough therapy designation for EGFR-mutated locally advanced or metastatic NSCLC.

The European Commission approved nirogacestat for the treatment of progressing desmoid tumors requiring systemic treatment.

Four expert hematologists discuss the FDA’s decision to remove REMS programs for CD19- and BCMA-directed CAR T-cell therapies in hematologic malignancies.

Adjuvant atezolizumab improved DFS and OS after a positive Signatera MRD test in muscle-invasive bladder cancer.

Hematology/oncology fellows shared insights on notable presentations given during the OncLive Fellows Forum on Thoracic Oncology.

Kevin Harrington, MBBS, MRCP, FRCR, FRCP, PhD, DIC, discusses ficerafusp alfa for the treatment of patients with HPV-negative head and neck cancer.

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

PLD plus ifosfamide produced an ORR of 33% and a DCR of 83% in advanced soft tissue sarcoma, with manageable toxicity.

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Ashish Saxena, MD, PhD, discusses how fellows can make the discussion of an initial cancer diagnosis as productive as possible for patients.

Neoadjuvant olaparib plus carboplatin led to a high RCB 0/1 rate in BRCA1/2-mutated, HRD+ TNBC.

TAR-200 was found to be highly effective in treating select patients with bladder cancer whose tumors were previously unresponsive to therapy.

Bortezomib plus mitoxantrone hydrochloride liposome and dexamethasone produced responses with manageable safety in relapsed/refractory myeloma

Nemvaleukin alfa produced a disease control rate of 50% in advanced melanoma and RCC.

The development of SGR-2921 in relapsed/refractory AML and higher-risk MDS was discontinued followed by 2 patient deaths.